Endothelial dysfunction and sympathetic nervous system activation in young patients with essential arterial hypertension and without hypercholesterolaemia

Acta Cardiologica

Volumn 65, Issue 5, 2010, Pages 535-540

  Kuklinska, Agnieszka M ^a   Mroczko, Barbara ^a   Musial, Wlodzimierz J ^a   Sawicki, Robert ^a   Kaminski, Karol ^a   Usowicz Szarynska, Monika ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Arterial hypertension; Endothelin 1; Epinephrine; hs C reactive protein; Norepinephrine

Indexed keywords

ADRENALIN; C REACTIVE PROTEIN; ENDOTHELIN 1; NORADRENALIN;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NORADRENALIN BLOOD LEVEL; PREDICTIVE VALIDITY; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; C-REACTIVE PROTEIN; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; EPINEPHRINE; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; NOREPINEPHRINE; SENSITIVITY AND SPECIFICITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 78149380138     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.65.5.2056240     Document Type: Article

References (16)

1. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002; 20: 1671-74.
2. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, noradrenaline reuptake, and angiotensin neuromodulation. Hypertension 2004; 43: 169-75. (Pubitemid 38174169)
3. Kim JS, Kang TS, Kim JB, Seo HS, Park S, Kim C, Ko YG, Choi D, Jang Y, Chung N. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 2007; 192: 401-6.
4. Boos CJ, Lip GY. Is hypertension an inflammatory process? Curr Pharm Des 2006; 12: 1623-35.
5. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiwicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Bretano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widymsky P, Zamorano JL, Kjeldsen SE, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struilker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
6. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34: 631-8.
7. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680-3. (Pubitemid 29485248)
8. Ozdogan M, Bozcuk H, Coban E. Low-grade inflammation in white-coat hypertension. Med Sci Monit 2007; 13: CR570-573.
9. rd, Egan BM, Player M, Geesey ME. Use of statins and blood pressure. Am J Hypertens 2007; 20: 937-41.
10. Nakhai-Pour HR, Grobbee DE, Bots ML, Muller M, van der Schouw YT. C-reactive protein and aortic stiffness and wave reflection in middle-aged and elderly men from the community. J Hum Hypertens 2007; 21: 949-55.
11. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007; 50: 723-8.
12. Kozan O, Buyukoztruk K, Ilerigelen B, Kabakci G, Koylan N, ICEBERG Investigators. The impact of plasma high-sensitivity C-reactive protein levels on cardiovascular risk stratification of hypertensive patients: results of the ICEBERG study. J Clin Hypertens 2007; 9: 500-5.
13. Parati G, Pomidossi G, Casadei R, Mancia G. Lack of altering reactions to intermittent cuff inflations during noninvasive blood pressure monitoring. Hypertension 1985; 7: 597-601. (Pubitemid 15033563)
14. Srinivas K, Bhaskar MV, Aruna Kumari R, Nagaraj K, Reddy KK. Antioxidants, lipid peroxidation and lipoproteins in primary hypertension. Indian Heart J 2000; 52: 285-8.
15. Campelo M, Polónia J, Serrão P, Cerqueira-Gomes M. Evaluation of the sympathetic nervous system using heart rate variability and plasma hormones in hypertensive patients treated with cilazapril and atenolol. Cardiology 1996; 87: 402-8.
16. Esler M, Rumantir M, Kaye D, Jennings G, Hastings J, Socratous F, Lambert G. Sympathetic nerve biology in essential hypertension. Clin Exp Pharmacol Physiol 2001; 28: 986-99.